A pharmaceutical composition for enhancing male erectile function comprising an erectile function-enhancing amount of an insulin-like growth factor selected from the group consisting of IGF-1 (Somatmedin-C) and analogue LR3 IGF1 in admixture with a pharmaceutically-acceptable diluents or carrier. Such compositions optionally further comprise compounds se¬lected from an androgen, particularly, testosterone and dihydrotestosterone, a vasodilator, PDES inhibitor and prostaglandin El.